56,562 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Acquired by WealthPlan Investment Management LLC

WealthPlan Investment Management LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 56,562 shares of the company's stock, valued at approximately $1,042,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versor Investments LP bought a new position in Hims & Hers Health in the third quarter valued at about $634,000. Los Angeles Capital Management LLC boosted its position in Hims & Hers Health by 40.8% during the third quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company's stock valued at $743,000 after purchasing an additional 11,686 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in Hims & Hers Health by 30.1% in the third quarter. State of New Jersey Common Pension Fund D now owns 123,587 shares of the company's stock valued at $2,276,000 after buying an additional 28,600 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after purchasing an additional 146,621 shares during the period. Finally, Olympiad Research LP purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $262,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HIMS. Truist Financial boosted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a "hold" rating in a report on Thursday, July 18th. Piper Sandler restated a "neutral" rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America raised their price objective on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, October 21st. TD Cowen lifted their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a "buy" rating in a research report on Friday. Finally, Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price for the company. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.21.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the firm's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the transaction, the director now owns 23,917 shares of the company's stock, valued at approximately $362,342.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Christiane Pendarvis sold 7,000 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares of the company's stock, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock valued at $15,987,230 over the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Down 4.3 %

HIMS stock traded down $1.19 during trading on Tuesday, reaching $26.69. The stock had a trading volume of 8,579,788 shares, compared to its average volume of 8,819,200. Hims & Hers Health, Inc. has a one year low of $6.68 and a one year high of $29.68. The company's 50 day moving average is $19.01 and its two-hundred day moving average is $18.60. The company has a market capitalization of $5.73 billion, a price-to-earnings ratio of 60.66 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) EPS. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.25 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.